Editas Medicine, Inc.
Key Metrics
Market Snapshot
About
Editas Medicine, Inc. is a clinical-stage biotechnology company focused on developing CRISPR gene editing therapies for serious diseases. The company's pipeline includes experimental treatments for inherited retinal diseases, sickle cell disease, cancer, and other genetic disorders using its proprietary CRISPR/Cas9 and Cas12a platforms. Editas is advancing multiple clinical trials including EDIT-101 for Leber congenital amaurosis 10, a rare form of inherited blindness. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company is among the pioneers commercializing CRISPR gene editing technology for human therapeutics.